HARBIN, China, July 12, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that on June 28, 2012 the Company attended the 47th session of the National New and Special Medicine Trade Fair (the "Trade Fair"), held in Qingdao, Shandong province.
The Trade Fair attracted more than 1,500 pharmaceutical companies and 70,000 visitors from around the world. At the Trade Fair, China Botanic exhibited a wide a range of products, including Siberian Ginseng Extract, Ginseng and Venison Extract, Banlangen Granules, Tianma Tablets, Compound Honeysuckle Granules, Shengmai Granules, Siberian Ginseng Tablet, and Badger Oil. The Company received a positive response from participants at the Trade Fair and has signed two Letters of Intent valued at approximately RMB2.8 million (US$0.4 million).
"We have received positive responses from participants at the Trade Fair. This event provides a great opportunity to market our products to players from China's pharmaceutical industry and increase awareness of our products and improve our corporate visibility," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are committed to participating in industry events which we believe help expand our market presence, brand recognition and drive revenue growth."
For more information on the Event, please visit http://www.newdrugschina.com/.
ABOUT CHINA BOTANIC PHARMACEUTICAL INCChina Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:CCG Investor Relations:China Botanic Pharmaceutical Inc.
Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact
Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162
|SOURCE China Botanic Pharmaceutical Inc.|
Copyright©2012 PR Newswire.
All rights reserved